Apnimed (APMD)
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related b...
- Open
- 26.600
- High
- 29.560
- Low
- 26.010
- Prev. Close
- 25.630
- Volume
- 362.41K
- Turnover
- 9.97M
- Avg Price
- 27.504
- Bid/Ask Ratio
- 15.79%
- Amplitude
- 13.85%
- 52wk High
- 35.290
- Volume Ratio
- 0.00
- Turnover Ratio
- 0.99%
Apnimed Analyst Rating
View moreForecast & Rating
Aug 25, 2026Price forecast
$41.0050.76%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 5 at 03:20 PM
Morningside Venture Investments reports Apnimed common share acquisition valued at $5 million
- IPO Scoop · Aug 3 at 10:53 PM
The IPO Buzz: Biotechs Turn Up the Heat in August
- Tip Ranks · Aug 3 at 09:08 PM
Insider Move: Apnimed Director Makes Bold New Investment
- PUBT · Aug 3 at 03:03 PM
Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposals
- PUBT · Aug 3 at 03:01 PM
Apnimed director Paul J. Sekhri acquires $200,000 in common shares
- StockTitan · Aug 3 at 07:35 AM
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | APMD Stock News
